- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Featured Articles and Interviews
More Featured Articles and Inverviews
Press Releases
More Press Releases
Overview
Isracann Biosciences Inc. (CSE:IPOT) is an Israeli-based cannabis company focused on becoming a premier low-cost cannabis producer. To this aim, the company is developing its fully-funded 230,000-square-foot cultivation facility near Tel Aviv, Israel. Isracann plans to target the undersupplied domestic and European markets with high-quality medical cannabis products manufactured at its facility.
The facility is being built to ISL and EU-GMP standards, and the company is applying for IMC-GAP and GSP certification, which allows Isracann to export its products and brands into Europe. The building is also designed to be a hybrid greenhouse, allowing the company to capitalize on Israel’s ideal climate and growing conditions.
Isracann’s Company Highlights
- Isracann is focused on becoming a premier low-cost cannabis producer in Israel and the EU.
- The European cannabis market is expected to be worth 123 billion euros by 2028.
- Isracann is developing a fully-funded 230,000-square-foot cultivation facility near Tel Aviv.
- Once complete, the facility can produce up to 23,500 kilograms of cannabis annually.
Get access to more exclusive Cannabis Stock profiles here.